Truist raised the firm’s price target on Medtronic (MDT) to $93 from $89 and keeps a Hold rating on the shares after its Q3 earnings beat. Despite the organic revenue miss, Medtronic saw high-single-digit EPS growth on underlying gross margin and operating leverage, the analyst tells investors in a research note. Truist adds that it is incrementally constructive on the stock amid the first “real” margin expansion quarter in years.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target raised to $85 from $83 at Goldman Sachs
- Medtronic price target raised to $91 from $90 at Baird
- Medtronic’s Strong Growth and Positive Outlook Reinforce Buy Rating Despite Challenges
- Medtronic Q3 Fiscal 2025 Financial Overview
- Medtronic’s Earnings Call Highlights Consistent Growth